Evaluation of prophylactic replacement therapy in haemophilia B

M. Morfini, P. M. Mannucci, G. Mariani, F. Panicucci, F. Petrucci, U. Baicchi, A. Capitanio, P. L. Ferrini, F. Mandelli

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Prophylaxis replacement therapy was assessed for a period of 12 months in 10 patients with severe haemophilia B showing a high incidence of spontaneous bleeding episodes. Two different schedules of administration of a freeze dried factor IX concentrate were randomly evaluated: according to scheme A, 7.5 U/kg were administered biweekly, whereas scheme B was based on the weekly infusion of 15 U/kg. On prophylaxis the frequency of bleeding episodes was significantly reduced (P <0.005) when compared with that observed in the one year period preceding the trial. Biweekly infusions were superior to weekly infusion (P <0.01), and the benefit appeared to be related to the higher number of days in which measurable levels of factor IX were attained in plasma. Range of motion, which was reduced at the start of the trial in 26 joints was found to have improved in 23. Favourable changes of the joint radiological picture were observed in 6 cases. Hepatitis and factor IX inhibitors did not develop during the trial period. Side effects were rare and mild.

Original languageEnglish
Pages (from-to)41-47
Number of pages7
JournalScandinavian Journal of Haematology
Volume16
Issue number1
Publication statusPublished - 1976

Fingerprint

Hemophilia B
Factor IX
Joints
Hemorrhage
Articular Range of Motion
Hepatitis
Appointments and Schedules
Incidence
Therapeutics
prothrombin complex concentrates

ASJC Scopus subject areas

  • Hematology

Cite this

Morfini, M., Mannucci, P. M., Mariani, G., Panicucci, F., Petrucci, F., Baicchi, U., ... Mandelli, F. (1976). Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology, 16(1), 41-47.

Evaluation of prophylactic replacement therapy in haemophilia B. / Morfini, M.; Mannucci, P. M.; Mariani, G.; Panicucci, F.; Petrucci, F.; Baicchi, U.; Capitanio, A.; Ferrini, P. L.; Mandelli, F.

In: Scandinavian Journal of Haematology, Vol. 16, No. 1, 1976, p. 41-47.

Research output: Contribution to journalArticle

Morfini, M, Mannucci, PM, Mariani, G, Panicucci, F, Petrucci, F, Baicchi, U, Capitanio, A, Ferrini, PL & Mandelli, F 1976, 'Evaluation of prophylactic replacement therapy in haemophilia B', Scandinavian Journal of Haematology, vol. 16, no. 1, pp. 41-47.
Morfini M, Mannucci PM, Mariani G, Panicucci F, Petrucci F, Baicchi U et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology. 1976;16(1):41-47.
Morfini, M. ; Mannucci, P. M. ; Mariani, G. ; Panicucci, F. ; Petrucci, F. ; Baicchi, U. ; Capitanio, A. ; Ferrini, P. L. ; Mandelli, F. / Evaluation of prophylactic replacement therapy in haemophilia B. In: Scandinavian Journal of Haematology. 1976 ; Vol. 16, No. 1. pp. 41-47.
@article{968a3e82b091485fab53ca039a66eb77,
title = "Evaluation of prophylactic replacement therapy in haemophilia B",
abstract = "Prophylaxis replacement therapy was assessed for a period of 12 months in 10 patients with severe haemophilia B showing a high incidence of spontaneous bleeding episodes. Two different schedules of administration of a freeze dried factor IX concentrate were randomly evaluated: according to scheme A, 7.5 U/kg were administered biweekly, whereas scheme B was based on the weekly infusion of 15 U/kg. On prophylaxis the frequency of bleeding episodes was significantly reduced (P <0.005) when compared with that observed in the one year period preceding the trial. Biweekly infusions were superior to weekly infusion (P <0.01), and the benefit appeared to be related to the higher number of days in which measurable levels of factor IX were attained in plasma. Range of motion, which was reduced at the start of the trial in 26 joints was found to have improved in 23. Favourable changes of the joint radiological picture were observed in 6 cases. Hepatitis and factor IX inhibitors did not develop during the trial period. Side effects were rare and mild.",
author = "M. Morfini and Mannucci, {P. M.} and G. Mariani and F. Panicucci and F. Petrucci and U. Baicchi and A. Capitanio and Ferrini, {P. L.} and F. Mandelli",
year = "1976",
language = "English",
volume = "16",
pages = "41--47",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Evaluation of prophylactic replacement therapy in haemophilia B

AU - Morfini, M.

AU - Mannucci, P. M.

AU - Mariani, G.

AU - Panicucci, F.

AU - Petrucci, F.

AU - Baicchi, U.

AU - Capitanio, A.

AU - Ferrini, P. L.

AU - Mandelli, F.

PY - 1976

Y1 - 1976

N2 - Prophylaxis replacement therapy was assessed for a period of 12 months in 10 patients with severe haemophilia B showing a high incidence of spontaneous bleeding episodes. Two different schedules of administration of a freeze dried factor IX concentrate were randomly evaluated: according to scheme A, 7.5 U/kg were administered biweekly, whereas scheme B was based on the weekly infusion of 15 U/kg. On prophylaxis the frequency of bleeding episodes was significantly reduced (P <0.005) when compared with that observed in the one year period preceding the trial. Biweekly infusions were superior to weekly infusion (P <0.01), and the benefit appeared to be related to the higher number of days in which measurable levels of factor IX were attained in plasma. Range of motion, which was reduced at the start of the trial in 26 joints was found to have improved in 23. Favourable changes of the joint radiological picture were observed in 6 cases. Hepatitis and factor IX inhibitors did not develop during the trial period. Side effects were rare and mild.

AB - Prophylaxis replacement therapy was assessed for a period of 12 months in 10 patients with severe haemophilia B showing a high incidence of spontaneous bleeding episodes. Two different schedules of administration of a freeze dried factor IX concentrate were randomly evaluated: according to scheme A, 7.5 U/kg were administered biweekly, whereas scheme B was based on the weekly infusion of 15 U/kg. On prophylaxis the frequency of bleeding episodes was significantly reduced (P <0.005) when compared with that observed in the one year period preceding the trial. Biweekly infusions were superior to weekly infusion (P <0.01), and the benefit appeared to be related to the higher number of days in which measurable levels of factor IX were attained in plasma. Range of motion, which was reduced at the start of the trial in 26 joints was found to have improved in 23. Favourable changes of the joint radiological picture were observed in 6 cases. Hepatitis and factor IX inhibitors did not develop during the trial period. Side effects were rare and mild.

UR - http://www.scopus.com/inward/record.url?scp=0017259368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017259368&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 41

EP - 47

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -